Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Demands Better Criteria for Selecting Comparator Drugs to Factor in Disease Features and Product Positioning
June 12, 2023
- PMP Company Criteria Mar Market Attractiveness, Scrap Them: FPMAJ
June 12, 2023
- Tide Has Changed, but That Doesn’t Erase Concerns: FPMAJ Drug Pricing Chief
June 12, 2023
- Regenerative Medicine Group Hails Expert Panel’s Proposal on New Pricing Method for Innovative Therapies
June 9, 2023
- JMA Renews Opposition for Health Coverage Review for Pharmaceuticals
June 8, 2023
- Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
June 7, 2023
- Industry’s Concerns Beginning to Sink in among Policymakers: JPMA Committee Chair
June 7, 2023
- Protect Info for Off-Patent Brands Even after Market Exit: JEMA
May 29, 2023
- Eisai’s Yasushi Okada Becomes FPMAJ Chairman
May 26, 2023
- New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
- 12 Medical and Nursing Care Groups Demand Responses to Inflation, Wage Hikes
May 26, 2023
- Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
- Prioritize Cardiovascular Disease on Health Policy Agenda: CfHH to G7
May 15, 2023
- Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
May 10, 2023
- JPMA Nudges Govt to Take Special Measures for Infectious Disease Biz
May 9, 2023
- JPWA Urges Govt to Take Steps against Drug Shortages Based on Overseas Examples
May 9, 2023
- Trade Group Demands Better Market Environment for Regenerative Medicine, Proposes New Pricing Model
April 28, 2023
- Health Care Science Institute Proposes Policies for Solving Distribution Issues, Reviewing Pricing System
April 26, 2023
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…